Melane Sampson, Author at BioTuesdays

Executive Moves

Dr. Ramón Polo joins Aligos as SVP, head of global and regulatory affairs

Aligos Therapeutics (NASDAQ: ALGS) has announced the appointment of Ramón Polo, PharmD, PhD, MBA as senior vice president, head of global regulatory affairs, effective immediately. Dr. Polo’s extensive background...

August 21, 2025

Developments

WHO, UNICEF rollout Afghanistan polio vaccination campaign with PharmaJet Tropis ID delivery system

Closely held PharmaJet has announced that its WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign sponsored by the National Emergency Operation Center (NEOC) Afghanistan...

August 19, 2025

Developments

Soligenix receives orphan drug designation for treatment of Behçet’s disease

Soligenix (NASDAQ: SNGX) has announced that the FDA has granted orphan drug designation to dusquetide—the active ingredient in SGX945—for the treatment of Behçet’s disease, upon review of Phase 2 trial results...

August 18, 2025

Developments

USPTO grants Unicycive’s UNI-494 patent for CKD

Unicycive Therapeutics (NASDAQ: UNCY) has announced that the U.S. Patent and Trademark Office has issued a patent for UNI-494 to treat chronic kidney disease (CKD). According to Unicycive, the patent follows the...

August 18, 2025

Developments

Swissmedic grants Mainz approval to market ColoAlert

Mainz Biomed (NASDAQ: MYNZ) has announced that its non-invasive colorectal cancer (CRC) screening test—ColoAlert—has been registered and approved for distribution by the Swiss regulatory and supervisory authority...

August 13, 2025

Developments

Trinity achieves breakthrough trial results for next-gen CGM sensor

Trinity Biotech (NASDAQ: TRIB) has announced compelling clinical trial results demonstrating a major technical breakthrough and de-risking the commercial pathway for its next-generation continuous glucose monitoring...

August 12, 2025

Developments

IGC reports positive preclinical data on IGC-M3 in Alzheimer’s

IGC Pharma (NYSE: IGC) has announced promising preclinical results of its novel small molecule, IGC-M3, designed to address multiple biological drivers of Alzheimer’s disease. According to IGC, IGC-M3 demonstrated...

August 12, 2025

Feature

Ascentage reviving programmed cell death with novel approach to hematologic malignancies

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is advancing its proprietary drug discovery platform of first- and best-in-class small molecule therapies to address unmet medical needs in cancers and other diseases.

August 12, 2025

Developments

NRx’s NRC-100 receives Fast Track Designation for suicide ideation in depression

NRx Pharmaceuticals (NASDAQ: NRXP) has announced that the FDA has granted NRC-100 Fast Track Designation as a standalone drug for the treatment of suicidal ideation in patients with depression, including bipolar...

August 11, 2025

Developments

FDA approves PharmaTher’s KETARx for surgical pain management

PharmaTher Holdings (QTCQB: PHRRF; CSE: PHRM) has announced that the FDA has approved its ketamine product, KETARx, for use in surgical pain management. According to PharmaTher, the approval positions the company to...

August 11, 2025

Author - Melane Sampson

Dr. Ramón Polo joins Aligos as SVP, head of global and regulatory affairs

WHO, UNICEF rollout Afghanistan polio vaccination campaign with PharmaJet Tropis ID delivery system

Soligenix receives orphan drug designation for treatment of Behçet’s disease

USPTO grants Unicycive’s UNI-494 patent for CKD

Swissmedic grants Mainz approval to market ColoAlert

Trinity achieves breakthrough trial results for next-gen CGM sensor

IGC reports positive preclinical data on IGC-M3 in Alzheimer’s

Ascentage reviving programmed cell death with novel approach to hematologic malignancies

NRx’s NRC-100 receives Fast Track Designation for suicide ideation in depression

FDA approves PharmaTher’s KETARx for surgical pain management

Subscribe